Recent clinical data suggest that KIM-1 can also be used as a biomarker for individuals that will go on to develop acute kidney injury following SARS-Co-V2 infection. DOI: 10.1007/s40620-021-01079-x

The inhibitor of TMPRSS2, N-0385, administered intranasally, has recently been shown to improve clinical outcomes in the severe K18-human ACE2 transgenic mouse model of SARS-CoV-2 disease. This is another potential novel therapeutic for patients suffering with COVID-19 (DOI: 10.1101/2021.05.03.442520).